Brown, Lisle/Cummings, Inc. Bristol Myers Squibb CO Transaction History
Brown, Lisle/Cummings, Inc.
- $376 Billion
- Q2 2025
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 19,000 shares of BMY stock, worth $884,450. This represents 0.23% of its overall portfolio holdings.
Number of Shares
19,000
Previous 16,738
13.51%
Holding current value
$884,450
Previous $1.02 Billion
13.84%
% of portfolio
0.23%
Previous 0.3%
Shares
15 transactions
Others Institutions Holding BMY
# of Institutions
2,662Shares Held
1.63BCall Options Held
24.8MPut Options Held
23.4M-
Vanguard Group Inc Valley Forge, PA195MShares$9.07 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.39 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY108MShares$5.03 Billion0.52% of portfolio
-
State Street Corp Boston, MA94.8MShares$4.41 Billion0.24% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA70.8MShares$3.3 Billion0.59% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...